• email
  • rss
  • twitter
  • facebook
  • linkedin
  • News
  • Investors
  • Contact

Ceapro Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Quality Management System
    • Sustainability
  • Technologies
    • Overview
    • Ethanol Fractionation Processes
    • Pressurized Gas Expanded (PGX) Technology
    • Chromatography Purification
    • Intellectual Property
    • Scientific Publications
  • Pipeline
    • Overview
    • Oat Beta Glucan
    • Avenanthramides
    • Product Brochures
  • Cosmeceuticals
    • Overview
  • Nutraceuticals
    • Overview
    • Oat Beta Glucan
    • Avenanthramides
  • Business Development
    • Overview
    • Partners
  • News
  • Investors
  • Contact
  • Home
  • Investors
  • News / Events
  • Press Releases
Navigation
  • Overview
  • News / Events
    • Press Releases
    • Events
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • Corporate Governance
  • SEDAR
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Press Releases

  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007

Ceapro Inc. Announces R&D Funding to Support PGX Technology Project

November 29, 2021

Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights

November 17, 2021

Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels

November 17, 2021

Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)

November 11, 2021

Ceapro Inc. to Present at the Virtual Investor Roundtable Event

November 10, 2021

Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights

August 26, 2021

Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides

August 23, 2021

Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide

August 11, 2021

Ceapro Announces Results of 2021 Shareholders’ Meeting

June 1, 2021

RSS
  • 1
  • 2
  • Next »

Sign up for email ALERTS Be the first to receive news and updates on Ceapro. Sign Up

  • © 2023 Ceapro Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap